콘텐츠로 건너뛰기
SOLUTIONS
Drug Discovery Sevices
Collaboration Partners
Platform
R&D
Platform Technology
Pipelines
Publications
Patent & Cert.
ABOUT US
Overview
History
Partnership
CI & BI
NEWS
Press Release
Seminars & Events
Notice
Responsibility
CAREER
Menu
SOLUTIONS
Drug Discovery Sevices
Collaboration Partners
Platform
R&D
Platform Technology
Pipelines
Publications
Patent & Cert.
ABOUT US
Overview
History
Partnership
CI & BI
NEWS
Press Release
Seminars & Events
Notice
Responsibility
CAREER
Get In Touch
The capabilities of PharmCADD’s vaccine platform are being verified through approval of a phase I/IIa trial for mRNA COVID-19 vaccine
News
09/09/2021
<View Original Article>
Post Views:
145
Prev
Previous
PharmCADD’s mRNA Vaccine design platform PharmVAC™: Eyegene Corona 19 vaccine candidate ‘EG-COVID’ mRNA sequence design
Next
The mayor, Hyung-Jun Park of Busan proposed vitalization of local human resource and knowledge leveraged by the collaboration among local governance, academy and industry
Next